Artiva Biotherapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Artiva Biotherapeutics

31/07/2026 12:04

Artiva Biotherapeutics Inc ARTV.OQ ARTV.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Artiva Biotherapeutics Inc is for a loss of 62 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Artiva Biotherapeutics Inc is $40.00, about 283.5% above its last closing price of $10.43
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.87
-0.87
-0.95
Missed
-8.9
Dec. 31 2026
-0.84
-0.83
-0.85
Missed
-2.9
Sep. 30 2025
-0.87
-0.87
-0.88
Missed
-1.1​
Jun. 30 2025
-0.80
-0.81
-0.87
Missed
-7.9
​​Mar. 31 2025
-0.71
-0.71
-0.83
Missed
-16.8
Dec. 31 2024
-0.74
-0.75
-0.66
Beat
12.6​
Sep. 30 2024
-0.91
-0.91
-0.92
Missed
-1.3
Jun. 30 2024
-4.40
-4.40
-22.00
Missed
-400.3
This summary was machine generated July 31 at 11:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)